For the Inventor, By the Inventor

Enter assignee name

Emeryville, CA, United States of America

Chiron Corporation

USPTO Granted Patents = 672

% Expired Patents = 12.9

CIPO Patents = 8

Trademarks = 11

Forward Citations = 20,520

Loading Chart...

Loading Chart...

597 inventors (with patents filed for the assignee):

Michael Houghton (53 out of 110 patents)

Michael S Urdea (51 out of 63 patents)

George Kuo (32 out of 36 patents)

4. Qui-Lim Choo (31 out of 42 patents)

5. Ronald N Zuckermann (28 out of 42 patents)

6. Thomas Horn (28 out of 35 patents)

7. Philip J Barr (24 out of 67 patents)

8. Robert F Halenbeck (24 out of 40 patents)

9. Kirston E Koths (24 out of 44 patents)

10. Pablo D Valenzuela (23 out of 27 patents)

11. Guy T Mullenbach (22 out of 24 patents)

12. David B Ring (21 out of 33 patents)

13. Patricia A Tekamp-Olson (20 out of 22 patents)

14. Brian David Warner (19 out of 38 patents)

15. Steven Rosenberg (19 out of 37 patents)

Core Competencies:

Polypeptoid

Heterocyclic Compounds

GSK3 Polypeptides

Anticancer Agents

Therapeutic Polypeptides

Gene Products

Cytokine Administration

Inhibitors

Growth Factor

Gene Delivery

Peptide Ligands

Proteomic Analyses

672 patents: Sort by Forward Citations

1. 8673842 - Polypeptoid pulmonary surfactants (2014-03-18),

2. 8114830 - Polypeptoid pulmonary surfactants (2012-02-14),

3. 7705117 - EGFH2 genes and gene products (2010-04-27),

4. 7423148 - Small molecule PI 3-kinase inhibitors and methods of their use (2008-09-09),

5. 7368459 - Heterocyclic compounds (2008-05-06),

6. 7368453 - Quinazolinone compounds with reduced bioaccumulation (2008-05-06),

7. 7368106 - Use of a promoter of T-cell expansion and an inducer of CD40 stimulation in the treatment or prevention of a pathologic state (2008-05-06),

8. 7361484 - GSK3 polypeptides (2008-04-22),

9. 7345046 - Heteroaryl-fused pyrimidinyl compounds as anticancer agents (2008-03-18),

10. 7338935 - Chromatographic separation of therapeutic polypeptides (2008-03-04),

11. 7329741 - Polynucleotides that hybridize to DP-75 and their use (2008-02-12),

12. 7326711 - Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents (2008-02-05),

13. 7291725 - Sos1 inhibitors (2007-11-06),

14. 7285539 - Activation of HCV-specific T cells (2007-10-23),

15. 7279554 - Notch receptor ligands and uses thereof (2007-10-09),

Company Overview

Chiron Corporation, based in Emeryville, California, specializes in the development of innovative polypeptide therapeutics. The company focuses on advanced research in polypeptoid and heterocyclic compounds, contributing to the creation of therapeutic agents aimed at combating cancer and other diseases. Their expertise encompasses a range of core technology topics, including GSK3 polypeptides, cytokine administration, and various inhibitors, positioning Chiron at the forefront of biopharmaceutical advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

672 Patents

#1 in Emeryville, CA

#170 in California

#743 in US

#1,477 in the World

Emeryville, CA, United States of America

Chiron Corporation

Forward Citations = 20,520

597 inventors:

Michael Houghton (53 out of 110 patents)

Michael S Urdea (51 out of 63 patents)

George Kuo (32 out of 36 patents)

4. Qui-Lim Choo (31 out of 42 patents)

5. Ronald N Zuckermann (28 out of 42 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Chiron Corporation. Retrieved from https://idiyas.com/company/chiron

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…